| Human hepatic organoids for the analysis of human genetic diseases Y Guan, D Xu, PM Garfin, U Ehmer, M Hurwitz, G Enns, S Michie, M Wu, ... JCI insight 2 (17), 2017 | 189 | 2017 |
| Prostacyclin release by rat cardiac fibroblasts: inhibition of collagen expression H Yu, AM Gallagher, PM Garfin, MP Printz Hypertension 30 (5), 1047-1053, 1997 | 96 | 1997 |
| Genomic analysis of fibrolamellar hepatocellular carcinoma L Xu, FK Hazard, AF Zmoos, N Jahchan, H Chaib, PM Garfin, ... Human molecular genetics 24 (1), 50-63, 2015 | 82 | 2015 |
| Inactivation of the RB family prevents thymus involution and promotes thymic function by direct control of Foxn1 expression PM Garfin, D Min, JL Bryson, T Serwold, B Edris, CC Blackburn, ... Journal of Experimental Medicine 210 (6), 1087-1097, 2013 | 68 | 2013 |
| Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study JJ Harding, J Fan, DY Oh, HJ Choi, JW Kim, HM Chang, L Bao, HC Sun, ... The Lancet Oncology 24 (7), 772-782, 2023 | 51 | 2023 |
| Expression of the Arf tumor suppressor gene is controlled by Tgfβ2 during development NE Freeman-Anderson, Y Zheng, AC McCalla-Martin, LM Treanor, ... Oxford University Press for The Company of Biologists Limited 136 (12), 2081 …, 2009 | 33 | 2009 |
| Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution PM Garfin, MP Link, SS Donaldson, RH Advani, S Luna-Fineman, ... Biology of Blood and Marrow Transplantation 21 (2), 326-334, 2015 | 27 | 2015 |
| Systematic literature review of the global incidence and prevalence of myelodysplastic syndrome and acute myeloid leukemia DP Lubeck, M Danese, D Jennifer, K Miller, A Richhariya, PM Garfin Blood 128 (22), 5930, 2016 | 21 | 2016 |
| 259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer M Tsai, HS Han, AJ Montero, KH Tkaczuk, H Assad, L Pusztai, SA Hurvitz, ... Annals of Oncology 32, S474-S475, 2021 | 19 | 2021 |
| Real-world economic burden associated with transplantation-related complications MA Perales, M Bonafede, Q Cai, PM Garfin, D McMorrow, NC Josephson, ... Biology of Blood and Marrow Transplantation 23 (10), 1788-1794, 2017 | 18 | 2017 |
| Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies M Bonafede, A Richhariya, Q Cai, NC Josephson, D McMorrow, ... Journal of medical economics 20 (12), 1244-1251, 2017 | 17 | 2017 |
| Antibody-based treatment of acute myeloid leukemia PM Garfin, EJ Feldman Current hematologic malignancy reports 11, 545-552, 2016 | 17 | 2016 |
| Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma R Chen, S Allibone, NL Bartlett, P Brice, A Chen, K Pose, L Rich, ... OncoTargets and therapy, 2027-2034, 2016 | 9 | 2016 |
| Loss of Pten disrupts the thymic epithelium and alters thymic function PM Garfin, T Nguyen, J Sage PLoS One 11 (2), e0149430, 2016 | 9 | 2016 |
| SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors. A Patnaik, F Meric-Bernstam, CMSP Rocha Lima, F Robert, A Dowlati, ... Journal of Clinical Oncology 38 (15_suppl), TPS3652-TPS3652, 2020 | 7 | 2020 |
| SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer. HC Beckwith, DC Medgyesy, J Abraham, R Nanda, KHR Tkaczuk, IE Krop, ... Journal of Clinical Oncology 38 (15_suppl), TPS1104-TPS1104, 2020 | 6 | 2020 |
| Human hepatic organoids for the analysis of human genetic diseases. JCI Insight. 2017; 2 (17) Y Guan, D Xu, PM Garfin, U Ehmer, M Hurwitz, G Enns | 5 | |
| Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC). S Pant, J Fan, DY Oh, HJ Choi, JW Kim, HM Chang, L Bao, HC Sun, ... Journal of Clinical Oncology 41 (16_suppl), 4008-4008, 2023 | 4 | 2023 |
| 323 Systemic administration of ladiratuzumab vedotin alone or in combination with pembrolizumab results in significant immune activation in the tumor microenvironment in … L Pusztai, H Lu, C Hale, A Grosse-Wilde, J Specht, S Modi, H Han, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 3 | 2020 |
| Abstract OT-03-03: SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer HC Beckwith, DC Medgyesy, J Abraham, R Nanda, KHR Tkaczuk, IE Krop, ... Cancer Research 81 (4_Supplement), OT-03-03-OT-03-03, 2021 | 2 | 2021 |
Julien SageProfessor of Pediatrics and Genetics, Stanford UniversityVerified email at stanford.edu
